Sativa Wellness Group Inc. is pleased to announce today that it has signed a distribution agreement with German partners Lexamed GMBH (“Lexamed”). This exclusive agreement will allow both parties to work together to build the Goodbody CBD brand within Germany with plans to expand this to other European countries in the future.
Sativa Wellness Group Inc. is pleased to announce today its first quarterly profit in Q2 2021. The Company has filed the Financial Statements and Management’s Discussion and Analysis for Q2 June 2021 with exceptionally strong results which demonstrates the continued growth.
Sativa Wellness is pleased to announce its new business strategy following a strong start to the year.
The Company announces that Marc Howells, Chief Executive Officer, has been awarded 1,447,173 options yesterday over 1,447,173 Common Shares of the Company (“Director Options”). The Director Options vest immediately, have an exercise price of 6.2 cents and are valid for 5 years.
Sativa Wellness Group Inc. is pleased to announce that today it will open its 40th clinic, and that it is also expected to list shortly through Patient Access.
Sativa Wellness Group Inc. is pleased to announce that following its collaboration with King’s College London, investigating the potential therapeutic use of cannabinoids for the treatment of respiratory diseases, a research paper including the results of part of this research has been published.
The Company announces that in accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules (the “Disclosure and Transparency Rules”), the total number of common shares of nil par value in the capital of the Company in issue as at the date of this notice is 364,615,913 with each share carrying the right to one vote.
Sativa Wellness Group Inc. is pleased to announce that it has filed the Financial Statements and Management’s Discussion and Analysis for Q1 March 2021. All amounts unless stated otherwise are presented in British Pounds (GBP).
The Company has maintained its presence within the CBD sector producing both quality isolate and distillate in Poland for the CBD market as well as continuing to produce a range of quality end products through its ‘Goodbody’ brand in the UK.
Sativa Wellness Group is pleased to announce, further to its news releases dated February 24, 2021 and April 8, 2021, it has closed the second and final tranche of the Company’s non-brokered private placement (the “Offering”) of units (the “Units”). Together with the first tranche closing of the Offering announced by the Company on April 8, 2021, the Company issued an aggregate 58,590,287 Units at a price of $0.07875 per Unit, for aggregate gross proceeds of $4,613,985.10.
Sativa Wellness is pleased to announce the publication of it Financial Statements and Management, Discussion and Analysis report for year ended December 31, 2020. The key highlights of 2020 can be summarised as follows:
2020 Financial Results
The turnover for 2020 was £1,994K (C$3,478K) which was a 38% increase on the previous year (£1,449K) and the gross profit margin at 56% was a 4% increase on the 52% of the previous year. This, in the year of a pandemic, was a great success.
Sativa Wellness is pleased to announce the appointment of Marc Howells as Director and Chief Executive Officer and Anne Tew as Director and Chief Financial Officer of the Company.
The Company wishes to thank both Geremy Thomas for his role as the interim CEO and Joseph Colliver as CFO for their contribution. Geremy Thomas will continue in his role as Executive Chairman.
Marc Howells has been appointed as a Director and CEO effective April 23, 2021 to deliver the Company’s strategy to become one of the best-known wellness brands.
Sativa Wellness Group is pleased to announce that the Company’s subsidiary PhytoVista Laboratories has been granted accreditation to ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories.
Accreditation for the testing of cannabinoids has been granted by United Kingdom Accreditation Service (UKAS), the UK governments appointed National Accreditation Body. The accreditation process determines the technical competence and integrity of organisations such as those offering testing services.